NewEdge Advisors LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 95,939 shares of the medical research company’s stock after selling 2,821 shares during the quarter. NewEdge Advisors LLC’s holdings in Amgen were worth $33,756,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in AMGN. Brighton Jones LLC lifted its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares in the last quarter. Schnieders Capital Management LLC. raised its holdings in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after buying an additional 5,853 shares during the period. Main Street Financial Solutions LLC raised its holdings in shares of Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after buying an additional 416 shares during the period. Finally, Ieq Capital LLC lifted its stake in Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after acquiring an additional 2,611 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.
Amgen Trading Down 0.7%
AMGN opened at $404.85 on Friday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $418.40. The stock has a market capitalization of $218.50 billion, a price-to-earnings ratio of 25.16, a PEG ratio of 4.10 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The business has a fifty day moving average price of $361.29 and a 200 day moving average price of $355.86.
Amgen Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is presently 70.15%.
More Amgen News
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen reported second-quarter revenue of $10.05 billion, up approximately 9.5% year over year, while adjusted EPS of $6.29 exceeded the roughly $5.62 analyst consensus. Growth across cardiovascular, bone-health, and rare-disease medicines helped offset pressure from older products facing biosimilar competition. Amgen second-quarter sales rise 9%, profit tops Street view
- Positive Sentiment: Management raised its 2026 outlook, with adjusted EPS guidance of $22.30 to $23.50 and revenue guidance of approximately $38.2 billion to $39.4 billion. The update reflects momentum across Amgen’s portfolio and continued progress in its late-stage pipeline. AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
- Positive Sentiment: Several firms raised their targets following the results. UBS lifted its target to $440 and TD Cowen to $452, while BMO, Oppenheimer, and Scotiabank set targets near $450 or higher; UBS and TD Cowen maintained bullish ratings. Amgen Price Target Raised to $440 at UBS
- Neutral Sentiment: Analyst sentiment remains divided. Citi maintained a Hold rating, while UBS retained Buy; other firms raised targets but kept Hold, Equal Weight, or Underperform ratings, suggesting some analysts believe the upgraded outlook is already reflected in the valuation. Citi Keeps Their Hold Rating on Amgen
- Negative Sentiment: Amgen abandoned an obesity-drug candidate, while pressure from biosimilars and weaker performance in some legacy franchises remains a headwind. Questions surrounding Tavneos clinical data add regulatory and reputational uncertainty. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
- Negative Sentiment: A reported patient-data breach has prompted a law-firm investigation into potential privacy claims, creating additional legal, operational, and reputational risk for Amgen. Amgen Data Breach Class Action Investigation
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. Argus lowered their target price on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Sanford C. Bernstein boosted their price target on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research report on Friday, June 5th. Wells Fargo & Company raised their price objective on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $367.93.
Get Our Latest Report on Amgen
Amgen Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Read More
- Five stocks we like better than Amgen
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
